For the last decade, researchers have used SELDI
technology to explore biomarkers for EM, and have found differential peaks at 8141, 6096, 5894, 3269, 3956.
Bio-Rad's sales force could provide a new market push for SELDI
, however, the company may be betting on the eventual development of diagnostic applications to drive technology sales.
has been used to identify novel biomarkers and signatures for ovarian cancer, (40) and prostate cancer.
The method, invented at Ciphergen, called "Differential Retentate Chromatography," is an advanced form of SELDI
(surface enhanced laser desorption/ionization) time-of-flight mass spectrometry.
is being investigated for potential use in serum biomarker development and classification of control and toxicant-exposed experimental animals.
was developed by the Fremont, CA-based company, Ciphergen, who make and distribute the instruments used for this research.
produces a more accurate spectrum of protein masses than gel electrophoresis, which is the more conventional but less precise means of separating proteins by mass.
Pall and Ciphergen also announced an alliance to develop and promote Ciphergen's patented SELDI
ProteinChip(R) technology as a bridge between the research lab and large scale drug production.
Daniel Chan of Johns Hopkins University discussed his lab's use of SELDI
chips to identify diagnostic biomarkers, but cautioned not to expect a clinical proteomics test in the near future.
Serum proteins are selectively bound to chemically active surfaces on SELDI
biochips and are rapidly scanned with high mass accuracy.
was developed by the Fremont, CA-based company Ciphergen, who makes and distributes the instruments used for this research.
Frost & Sullivan recognized Ciphergen's ingenuity in developing the ProteinChip(R) System based on SELDI
technology by honoring the company with the Proteomics Technology of the Year Award.